Half-life
~6 days
SKUs Available
8
Evidence Level
High Evidence
Mechanism of Action
Simultaneous activation of GIP, GLP-1, and glucagon receptors — the first triagonist studied in human clinical trials.
Published Research Ranges & Study Context
Studies have administered: 1–12mg weekly in Phase 2 trials
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Phase 2 trial (JAMA 2023) reported up to 24.2% weight reduction at 48 weeks — highest reported in a peptide trial to date.
High Evidence
Multiple large human RCTs available
Side Effects Observed in Research
GI symptoms similar to GLP-1 class; dose-dependent nausea during uptitration
Available Configurations (SKU Reference)
RT5
RT10
RT15
RT20
RT30
RT40
RT50
RT60
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Retatrutide — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.